SALT LAKE CITY, Utah — March 2, 2026 — Leads & Copy — Myriad Genetics, Inc. (NASDAQ: MYGN) has announced the launch of its Precise MRD™ (molecular residual disease) test for breast cancer patients, available through select oncology practices.
The Precise MRD test is designed to monitor cancer treatment by detecting circulating tumor DNA (ctDNA). The test uses whole-genome sequencing to create a personalized assay for each patient, enabling the detection of ctDNA down to one part per million.
Brian Donnelly, Chief Commercial Officer of Myriad Genetics, said the launch of Precise MRD marks a significant advancement in cancer care, providing earlier insights and supporting more informed treatment decisions. He added that this launch highlights Myriad’s ability to deliver diagnostics on schedule.
According to Dr. Derrick S. Haslem, ACMO of Specialty Care at Intermountain Health in Desert Region, Precise MRD testing can detect cancer cells that persist after treatment but remain undetectable through conventional methods. In the initial phase, the test will be available to community oncologists treating breast cancer patients, with no restrictions on the number of patients participating. A broader commercial launch across the U.S. is planned for later this year.
Dr. Sucharu Prakash, Director of Quality Services for Texas Oncology and Past President of Texas Society of Clinical Oncology, said that Precise MRD offers improved visibility into treatment effectiveness, especially benefiting patients in rural areas who face challenges with frequent screening tests. He believes the test is a key tool for determining personalized cancer treatments.
The Precise MRD test can assist clinicians in determining the need for adjuvant treatment or detecting cancer recurrence. It can also provide molecular insights into the effectiveness of treatment and identify increasing ctDNA levels in patients with metastatic cancer.
For initial tests, a custom panel is developed using a whole-genome sequencing profile of tumor tissue to measure ctDNA levels from a blood sample. For ongoing monitoring, ctDNA levels are measured from samples collected at intervals based on the patient’s treatment stage.
Clinicians will receive reports indicating whether ctDNA was detected and, if so, the concentration of ctDNA, allowing them to track changes over time.
Learn more at myriad.com/oncology/precise-mrd-test/.
Myriad Genetics is focused on advancing health and well-being through molecular diagnostics. It develops and commercializes molecular tests to provide genetic insights, assess disease risk and progression, and guide treatment decisions.
Source: Myriad Genetics
